Cellular vaccine therapy for cancer

Expert Review of Vaccines

Volumn 1, Issue 3, 2002, Pages 303-316

  Armstrong, Anne C ^a   Eaton, David ^a   Ewing, Joanne C ^a  

^a CHRISTIE HOSPITAL   (United Kingdom)

Author keywords

Allogeneic lymphocytes; Costimulatory molecule; Cytokine; Dendritic cell; Tumor antigen

Indexed keywords

BCG VACCINE; CANCER VACCINE; TUMOR ANTIGEN; TUMOR CELL VACCINE;

ADOPTIVE IMMUNOTHERAPY; ANTINEOPLASTIC ACTIVITY; AUTOIMMUNITY; CANCER IMMUNOTHERAPY; CLINICAL TRIAL; COLON CANCER; DENDRITIC CELL; HUMAN; IMMUNE RESPONSE; IMMUNOMODULATION; IMMUNOSURVEILLANCE; KIDNEY CANCER; NONHUMAN; PRIORITY JOURNAL; REVIEW; T LYMPHOCYTE; TREATMENT OUTCOME; TUMOR IMMUNITY;

ANIMALS; ANTIGENS, NEOPLASM; AUTOIMMUNITY; CANCER VACCINES; DENDRITIC CELLS; HUMANS; IMMUNITY, CELLULAR; IMMUNOTHERAPY, ADOPTIVE; NEOPLASMS; T-LYMPHOCYTES;

EID: 0038330646     PISSN: 14760584     EISSN: None     Source Type: Journal    
DOI: 10.1586/14760584.1.3.303     Document Type: Review

References (109)

1. Coley W. The treatment of malignant tumours by repeated inoculations of erysipelas: with a report of ten original cases. Am. J. Med. Sci. 105, 487-511 (1983).
2. Aguilar LK, Rooney CM, Heslop HE. Lymphoproliferative disorders involving Epstein-Barr virus after hemopoietic stem cell transplantation. Curr. Opin. Oncol. 11(2), 96-101 (1999).
3. Atkins MB, Lotze MT, Dutcher JP et al. High-dose recombinant interleukin-2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993. J. Clin. Oncol. 17(7), 2105-2116 (1999).
4. Fyfe G, Fisher RI, Rosenberg SA, Sznol M, Parkinson DR, Louie AC. Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy. J. Clin. Oncol. 13(3), 688-696 (1995).
5. Banchereau J, Steinman RM. Dendritic cells and the control of immunity. Nature 392(6673), 245-252 (1998).
6. Caux C, Massacrier C, Vanbervliet B et al. Activation of human dendritic cells through CD40 cross-linking. J. Exp. Med. 180(4), 1263-1272 (1994).
7. Buelens C, Verhasselt V, De Groote D, Thielemans K, Goldman M, Willems F. Human dendritic cell responses to lipopolysaccharide and CD40 ligation are differentially regulated by interleukin-10. Eur. J. Immunol. 27(8), 1848-1852 (1997).
8. Hartmann G, Weiner GJ, Krieg AM. CpG DNA: a potent signal for growth, activation and maturation of human dendritic cells. Proc. Natl Acad. Sci. USA 96(16), 9305-9310 (1999).
9. Matzinger P. Tolerance, danger and the extended family. Ann. Rev. Immunol. 12, 991-1045 (1994).
10. Cella M, Scheidegger D, Palmer-Lehmann K, Lane P, Lanzavecchia A, Alber G. Ligation of CD40 on dendritic cells triggers production of high levels of interleukin-12 and enhances T-cell stimulatory capacity: T-T help via APC activation. J. Exp. Med 184(2), 747-752 (1996).
11. Wong BR, Josien R, Lee SY et al. TRANCE (tumor necrosis factor (TNF)-related activation-induced cytokine), a new TNF family member predominantly expressed in T-cells, is a dendritic cell-specific survival factor. J. Exp. Med. 186(12), 2075-2080 (1997).
12. Ehrlich P. Ueber den jetzigen Stand der Karzinomforschung. Nederl Tijdschr v Geneesk 5, 273-290 (1909).
13. Burnet F. Immunological aspects of malignant disease. Lancet 1, 1171-1174 (1967).
14. Ferrone S, Marincola FM. Loss of HLA class I antigens by melanoma cells: molecular mechanisms, functional significance and clinical relevance. Immunol. Today 16(10), 487-494 (1995).
15. Cannon M, Cesarman E. Kaposi's sarcoma-associated herpes virus and acquired immunodeficiency syndrome-related malignancy. Semin. Oncol. 27(4), 409-419 (2000).
16. Penn I. Depressed immunity and the development of cancer. Cancer Detect. Prev. 18(4), 241-252 (1994).
17. Stutman O. Immunodepression and malignancy. Adv. Cancer Res. 22, 261-422 (1975).
18. Shankaran V, Ikeda H, Bruce AT et al. IFN-gamma and lymphocytes prevent primary tumour development and shape tumour immunogenicity. Nature 410(6832), 1107-1111 (2001).
19. Kaplan DH, Shankaran V, Dighe AS et al. Demonstration of an interferon gamma-dependent tumor surveillance system in immunocompetent mice. Proc. Natl Acad. Sci. USA 95(13), 7556-7561 (1998).
20. Smyth MJ, Thia KY, Street SE, MacGregor D, Godfrey DI, Trapani JA. Perforin-mediated cytotoxicity is critical for surveillance of spontaneous lymphoma. J. Exp. Med. 192(5), 755-760 (2000).
21. van den Broek ME, Kagi D, Ossendorp F et al. Decreased tumor surveillance in perforin-deficient mice. J. Exp. Med. 184(5), 1781-1790 (1996).
22. Shiku H, Takahashi T, Oettgen HF. Cell surface antigens of human malignant melanoma. II. Serological typing with immune adherence assays and definition of two new surface antigens. J. Exp. Med. 144(4), 873-881 (1976).
23. van der Bruggen P, Traversari C, Chomez P et al. A gene encoding an antigen recognized by cytolytic T-lymphocytes on a human melanoma. Science 254(5038), 1643-1647 (1991).
24. Topalian SL, Rivoltini L, Mancini M, Ng J, Hartzman RJ, Rosenberg SA. Melanoma-specific CD4+ T-lymphocytes recognize human melanoma antigens processed and presented by Epstein-Barr virus-transformed B-cells. Int. J. Cancer 58(1), 69-79 (1994).
25. Gaugler B, Van den Eynde B, van der Bruggen P et al. Human gene MAGE-3 codes for an antigen recognized on a melanoma by autologous cytolytic T-lymphocytes. J. Exp. Med. 179(3), 921-930 (1994).
26. Liu Z, Savoldo B, Huls H et al. Epstein-Barr virus (EBV)-specific cytotoxic T-lymphocytes for the prevention and treatment of EBV-associated posttransplant lymphomas. Recent Results Cancer Res. 159, 123-133 (2002).
27. Renkvist N, Castelli C, Robbins PF, Parmiani G. A listing of human tumor antigens recognized by T-cells. Cancer Immunol. Immunother. 50(1), 3-15 (2001).
28. Lee PP, Yee C, Savage PA et al. Characterization of circulating T-cells specific for tumor-associated antigens in melanoma patients. Nat. Med. 5(6), 677-685 (1999).
29. Staveley-O'Carroll K, Sotomayor E, Montgomery J et al. Induction of antigen-specific T-cell anergy. An early event in the course of tumor progression. Proc. Natl Acad. Sci. USA 95(3), 1178-1183 (1998).
30. Antonia SJ, Extermann M, Flavell RA. Immunologic nonresponsiveness to tumors. Crit. Rev. Oncol. 9(1), 35-41 (1998).
31. Pardoll DM. Cancer vaccines. Nat. Med. 4(Suppl. 5), 525-531 (1998).
32. Marincola FM, Jaffee EM, Hicklin DJ, Ferrone S. Escape of human solid tumors from T-cell recognition: molecular mechanisms and functional significance. Adv. Immunol. 74, 181-273 (2000).
33. Stoler DL, Chen N, Basik M et al. The onset and extent of genomic instability in sporadic colorectal tumor progression. Proc. Natl Acad. Sci. USA 96(26), 15121-15126 (1999).
34. Hanna MG Jr, Peters LC. Specific immunotherapy of established visceral micrometastases by BCG-tumor cell vaccine alone or as an adjunct to surgery. Cancer 42(6), 2613-2625 (1978).
35. Shu SY, Rosenberg SA. Adoptive immunotherapy of newly induced murine sarcomas. Cancer Res. 45(4), 1657-1662 (1985).
36. Hoover HC Jr, Brandhorst JS, Peters LC et al. Adjuvant active specific immunotherapy for human colorectal cancer: 6.5-year median follow-up of a Phase III prospectively randomized trial. J. Clin. Oncol. 11(3), 390-399 (1993).
37. Vermorken JB, Claessen AM, van Tinteren H et al. Active specific immunotherapy for stage II and stage III human colon cancer: a randomised trial. Lancet 353(9150), 345-350 (1999).
38. Harris JE, Ryan L, Hoover HC Jr et al. Adjuvant active specific immunotherapy for stage II and III colon cancer with an autologous tumor cell vaccine: Eastern Co-operative Oncology Group Study E5283. J. Clin. Oncol. 18(1), 148-157 (2000).
39. Hanna MG Jr, Hoover HC Jr, Vermorken JB, Harris JE, Pinedo HM. Adjuvant active specific immunotherapy of stage II and stage III colon cancer with an autologous tumor cell vaccine: first randomized Phase III trials show promise. Vaccine 19(17-19), 2576-2582 (2001).
40. Dranoff G, Jaffee E, Lazenby A et al. Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific and long-lasting antitumor immunity. Proc. Natl Acad. Sci. USA 90(8), 3539-3543 (1993).
41. Townsend SE, Allison JP. Tumor rejection after direct costimulation of CD8+ T-cells by B7-transfected melanoma cells. Science 259(5093), 368-370 (1993).
42. Dunussi-Joannopoulos K, Krenger W, Weinstein HJ, Ferrara JL, Croop JM. CD8+ T-cells activated during the course of murine acute myelogenous leukemia elicit therapeutic responses to late B7 vaccines after cytoreductive treatment. Blood 89(8), 2915-2924 (1997).
43. Antonia SJ, Seigne J, Diaz J et al. Phase I trial of a B7-1 (CD80) gene modified autologous tumor cell vaccine in combination with systemic interleukin-2 in patients with metastatic renal cell carcinoma. J. Urol. 167(5), 1995-2000 (2002).
44. Simons JW, Jaffee EM, Weber CE et al. Bioactivity of autologous irradiated renal cell carcinoma vaccines generated by ex vivo granulocyte-macrophage colony-stimulating factor gene transfer. Cancer Res. 57(8), 1537-1546 (1997).
45. Albert ML, Sauter B, Bhardwaj N. Dendritic cells acquire antigen from apoptotic cells and induce class I-restricted CTLs. Nature 392(6671), 86-89 (1998).
46. Bender A, Bui LK, Feldman MA, Larsson M, Bhardwaj N. Inactivated influenza virus, when presented on dendritic cells, elicits human CD8+ cytolytic T-cell responses. J. Exp. Med. 182(6), 1663-1671 (1995).
47. Yrlid U, Wick MJ. Salmonella-induced apoptosis of infected macrophages results in presentation of a bacteria-encoded antigen after uptake by bystander dendritic cells. J. Exp. Med. 191(4), 613-624 (2000).
48. Parlato S, Santini SM, Lapenta C et al. Expression of CCR-7, MIP-3beta and Th-1 chemokines in Type I IFN induced monocyte-derived dendritic cells: importance for the rapid acquisition of potent migratory and functional activities. Blood 98(10), 3022-3029 (2001).
49. Fong L, Engleman EG. Dendritic cells in cancer immunotherapy. Ann. Rev. Immunol. 18, 245-273 (2000).
50. Klein C, Bueler H, Mulligan RC. Comparative analysis of genetically modified dendritic cells and tumor cells as therapeutic cancer vaccines. J. Exp. Med 191(10), 1699-1708 (2000).
51. Meng WS, Butterfield LH, Ribas A et al. alpha-Fetoprotein-specific tumor immunity induced by plasmid prime-adenovirus boost genetic vaccination. Cancer Res. 61(24), 8782-8786 (2001).
52. Wang J, Saffold S, Cao X, Krauss J, Chen W. Eliciting T-cell immunity against poorly immunogenic tumors by immunization with dendritic cell-tumor fusion vaccines. J. Immunol. 161(10), 5516-5524 (1998).
53. Gong J, Chen D, Kashiwaba M et al. Reversal of tolerance to human MUC1 antigen in MUC1 transgenic mice immunized with fusions of dendritic and carcinoma cells. Proc. Natl Acad. Sci. USA 95(11), 6279-6283 (1998).
54. Kugler A, Stuhler G, Walden P et al. Regression of human metastatic renal cell carcinoma after vaccination with tumor cell-dendritic cell hybrids. Nat. Med. 6(3), 332-336 (2000).
55. Arthur JF, Butterfield LH, Roth MD et al. A comparison of gene transfer methods in human dendritic cells. Cancer Gene Ther. 4(1), 17-25 (1997).
56. Brossart P, Goldrath AW, Butz EA, Martin S, Bevan MJ. Virus-mediated delivery of antigenic epitopes into dendritic cells as a means to induce CTL. J. Immunol. 158(7), 3270-3276 (1997).
57. Kaplan JM, Yu Q, Piraino ST et al. Induction of antitumor immunity with dendritic cells transduced with adenovirus vector-encoding endogenous tumor-associated antigens. J. Immunol. 163(2), 699-707 (1999).
58. Timmerman JM, Caspar CB, Lambert SL, Syrengelas AD, Levy R. Idiotype-encoding recombinant adenovirus provide protective immunity against murine B-cell lymphomas. Blood 97(5), 1370-1377 (2001).
59. Lindemann C, Schilz AJ, Emons B et al. Downregulation of retroviral transgene expression during differentiation of progenitor-derived dendritic cells. Exp. Hematol. 30(2), 150-157 (2002).
60. Nair SK, Morse M, Boczkowski D et al. Induction of tumor-specific cytotoxic T-lymphocytes in cancer patients by autologous tumor RNA-transfected dendritic cells. Ann. Surg. 235(4), 540-549 (2002).
61. Nair SK, Boczkowski D, Morse M, Cumming RI, Lyerly HK, Gilboa E. Induction of primary carcinoembryonic antigen (CEA)-specific cytotoxic T-lymphocytes in vitro using human dendritic cells transfected with RNA. Nat. Biotechnol. 16(4), 364-369 (1998).
62. Boczkowski D, Nair SK, Snyder D, Gilboa E. Dendritic cells pulsed with RNA are potent antigen-presenting cells in vitro and in vivo. J. Exp. Med. 184(2), 465-472 (1996).
63. Ashley DM, Faiola B, Nair S, Hale LP, Bigner DD, Gilboa E. Bone marrow-generated dendritic cells pulsed with tumor extracts or tumor RNA induce antitumor immunity against central nervous system tumors. J. Exp. Med. 186(7), 1177-1182 (1997).
64. Heiser A, Coleman D, Dannull J et al. Autologous dendritic cells transfected with prostate-specific antigen RNA stimulate CTL responses against metastatic prostate tumors. J. Clin. Invest. 109(3), 409-417 (2002).
65. Dhodapkar MV, Steinman RM, Krasovsky J, Munz C, Bhardwaj N. Antigen-specific inhibition of effector T-cell function in humans after injection of immature dendritic cells. J. Exp. Med. 193(2), 233-238 (2001).
66. Bender A, Sapp M, Schuler G, Steinman RM, Bhardwaj N. Improved methods for the generation of dendritic cells from nonproliferating progenitors in human blood. J. Immunol. Methods 196(2), 121-135 (1996).
67. Romani N, Reider D, Heuer M et al. Generation of mature dendritic cells from human blood. An improved method with special regard to clinical applicability. J. Immunol. Methods 196(2), 137-151 (1996).
68. Pulendran B, Banchereau J, Maraskovsky E, Maliszewski C. Modulating the immune response with dendritic cells and their growth factors. Trends Immunol. 22(1), 41-47 (2001).
69. Serody JS, Collins EJ, Tisch RM, Kuhns JJ, Frelinger JA. T-cell activity after dendritic cell vaccination is dependent on both the type of antigen and the mode of delivery. J. Immunol. 164(9), 4961-4967 (2000).
70. Klein E, Sjogren H. Humoral and cellular factors in homograft and isograft immunity. Cancer Res. 20,452 (1960).
71. Rosenberg SA, Yang JC, White DE, Steinberg SM. Durability of complete responses in patients with metastatic cancer treated with high-dose interleukin-2: identification of the antigens mediating response. Ann. Surg. 228(3), 307-319 (1998).
72. Vlasveld LT, Rankin EM. Recombinant interleukin-2 in cancer: basic and clinical aspects. Cancer Treat. Rev. 20(3), 275-311 (1994).
73. Rosenberg SA, Lotze MT, Yang JC et al. Prospective randomized trial of high-dose interleukin-2 alone or in conjunction with lymphokine-activated killer cells for the treatment of patients with advanced cancer. J. Natl Cancer Inst. 85(8), 622-632 (1993).
74. Rosenberg SA, Spiess P, Lafreniere R. A new approach to the adoptive immunotherapy of cancer with tumor-infiltrating lymphocytes. Science 233(4770), 1318-1321 (1986).
75. Rosenberg SA, Yannelli JR, Yang JC et al. Treatment of patients with metastatic melanoma with autologous tumor-infiltrating lymphocytes and interleukin-2. J. Natl Cancer Inst. 86(15), 1159-1166 (1994).
76. Chang AE, Li Q, Jiang G, Sayre DM, Braun TM, Redman BG. A Phase II trial of antiCD3 activated, vaccine-primed lymphocytes in stage IV renal cell cancer. ASCO Proc. 2002:abstract 10.
77. Eshhar Z, Waks T, Gross G, Schindler DG. Specific activation and targeting of cytotoxic lymphocytes through chimeric single chains consisting of antibody -binding domains and the gamma or zeta subunits of the immunoglobulin and T-cell receptors. Proc. Natl Acad. Sci. USA 90(2), 720-724 (1993).
78. Hwu P, Yang JC, Cowherd R et al. In vivo antitumor activity of T-cells redirected with chimeric antibody/T-cell receptor genes. Cancer Res. 55(15), 3369-3373 (1995).
79. Hombach A, Wieczarkowiecz A, Marquardt T et al. Tumor-specific T-cell activation by recombinant immunoreceptors: CD3 zeta signaling and CD28 costimulation are simultaneously required for efficient IL-2 secretion and can be integrated into one combined CD28/ CD3 zeta signaling receptor molecule. J. Immunol. 167(11), 6123-6131 (2001).
80. Alvarez-Vallina L, Hawkins RE. Antigen-specific targeting of CD28-mediated T-cell co-stimulation using chimeric single-chain antibody variable fragment-CD28 receptors. Eur. J. Immunol. 26(10), 2304-2309 (1996).
81. Niederman TM, Ghogawala Z, Carter BS, Tompkins HS, Russell MM, Mulligan RC. Antitumor activity of cytotoxic T-lymphocytes engineered to target vascular endothelial growth factor receptors. Proc. Natl Acad. Sci. USA 99(10), 7009-7014 (2002).
82. Treisman J, Hwu P, Minamoto S et al. Interleukin-2-transduced lymphocytes grow in an autocrine fashion and remain responsive to antigen. Blood 85(1), 139-145 (1995).
83. Eaton D, Gilham DE, O'Neill A, Hawkins RE. Retroviral transduction of human peripheral blood lymphocytes with Bcl-X(L) promotes in vitro lymphocyte survival in pro-apoptotic conditions. Gene Ther. 9(8), 527-535 (2002).
84. Schiavo R, Cormoli P, Pedrazzoli P et al. Epstein-Barr (EBV)-specific cytoxic T-lymphocytes (CTLs) for therapy of nasopharyngeal carcinoma (NPC). ASCO Proc. abstract 103 (2002).
85. Rooney CM, Smith CA, Ng CY et al. Use of gene-modified virus-specific T-lymphocytes to control Epstein-Barr-virus-related lymphoproliferation. Lancet 345(8941), 9-13 (1995).
86. Goulmy E, Schipper R, Pool J et al. Mismatches of minor histocompatibility antigens between HLA-identical donors and recipients and the development of graft versus host disease after bone marrow transplantation. N. Engl. J. Med. 334(5), 281-285 (1996).
87. Childs R, Chernoff A, Contentin N et al. Regression of metastatic renal-cell carcinoma after nonmyeloablative allogeneic peripheral-blood stem-cell transplantation. N. Engl. J. Med. 343(11), 750-758 (2000).
88. Bregni M, Dodero A, Peccatori J et al. Nonmyeloablative conditioning followed by hematopoietic cell allografting and donor lymphocyte infusions for patients with metastatic renal and breast cancer. Blood 99(11), 4234-4236 (2002).
89. Bonini C, Ferrari G, Verzeletti S et al. HSV-TK gene transfer into donor lymphocytes for control of allogeneic graft-versus-leukemia. Science 276(5319), 1719-124 (1997).
90. Fontaine P, Roy-Proulx G, Knafo L, Baron C, Roy DC, Perreault C. Adoptive transfer of minor histocompatibility antigen-specific T-lymphocytes eradicates leukemia cells without causing graft versus host disease. Nat. Med. 7(7), 789-794 (2001).
91. Bonnet D, Warren EH, Greenberg PD, Dick JE, Riddell SR. CD8(+) minor histocompatibility antigen-specific cytotoxic T-lymphocyte clones eliminate human acute myeloid leukemia stem cells. Proc. Natl Acad. Sci. USA 96(15), 8639-8644 (1999).
92. Mutis T, Verdijk R, Schrama E, Esendam B, Brand A, Goulmy E. Feasibility of immunotherapy of relapsed leukemia with ex vivo-generated cytotoxic T-lymphocytes specific for hematopoietic system-restricted minor histocompatibility antigens. Blood 93(7), 2336-2341 (1999).
93. Mutis T, Blokland E, Kester M, Schrama E, Goulmy E. Generation of minor histocompatibility antigen HA-1 specific cytotoxic T-cells restricted by non-self HLA molecules: a potential strategy to treat relapsed leukaemia after HLA-mismatched stem cell transplantation. Blood 100(2), 547-552 (2002).
94. Clave E, Molldrem J, Hensel N, Raptis A, Barrett AJ. Donor-recipient polymorphism of the proteinase 3 gene: a potential target for T-cell alloresponses to myeloid leukemia. J. Immunother.22(1), 1-6 (1999).
95. Molldrem JJ, Lee PP, Wang C et al. Evidence that specific T-lymphocytes may participate in the elimination of chronic myelogenous leukemia. Nat. Med. 6(9), 1018-1023 (2000).
96. Molldrem JJ, Lee PP, Wang C, Champlin RE, Davis MM. A PR1-human leukocyte antigen-A2 tetramer can be used to isolate low- frequency cytotoxic T-lymphocytes from healthy donors that selectively lyse chronic myelogenous leukemia. Cancer Res. 59(11), 2675-2681 (1999).
97. Molldrem JJ, Clave E, Jiang YZ et al. Cytotoxic T-lymphocytes specific for a nonpolymorphic proteinase 3 peptide preferentially inhibit chronic myeloid leukemia colony-forming units. Blood 90(7), 2529-2534 (1997).
98. Gao L, Bellantuono I, Elsasser A et al. Selective elimination of leukemic CD34(+) progenitor cells by cytotoxic T-lymphocytes specific for WT1. Blood 95(7), 2198-203 (2000).
99. Ohminami H, Yasukawa M, Fujita S. HLA class I-restricted lysis of leukemia cells by a CD8(+) cytotoxic T-lymphocyte done specific for WT1 peptide. Blood 95 (1), 286-293 (2000).
100. Gaiger A, Reese V, Disis ML, Cheever MA. Immunity to WT1 in the animal model and in patients with acute myeloid leukemia. Blood 96(4), 1480-1489 (2000).
101. Ludewig B, Ochsenbein AF, Odermatt B, Paulin D, Hengartner H, Zinkernagel RM. Immunotherapy with dendritic cells directed against tumor antigens shared with normal host cells results in severe autoimmune disease. J. Exp. Med. 191(5), 795-804 (2000).
102. Rosenberg SA, White DE. Vitiligo in patients with melanoma: normal tissue antigens can be targets for cancer immunotherapy. J. Immunother. Emphasis Tumor Immunol. 19(1), 81-84 (1996).
103. Mayordomo JI, Loftus DJ, Sakamoto H et al. Therapy of murine tumors with p53 wild type and mutant sequence peptide-based vaccines. J. Exp. Med. 183(4), 1357-1365 (1996).
104. Vierboom MP, Nijman HW, Offringa R et al. Tumor eradication by wild type p53-specific cytotoxic T-lymphocytes. J. Exp. Med. 186(5), 695-704 (1997).
105. Morgan DJ, Kreuwel HT, Fleck S, Levitsky HI, Pardoll DM, Sherman LA. Activation of low avidity CTL specific for a self epitope results in tumor rejection but not autoimmunity. J. Immunol. 160(2), 643-51 (1998).
106. Keilholz U, Weber J, Finke JH et al. Immunologic monitoring of cancer vaccine therapy: results of a workshop sponsored by the society for biological therapy. J. Immunother. 25(2), 97-138 (2002).
107. Polychemotherapy for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group. Lancet 352(9132), 930-942 (1998).
108. Van't Veer LJ, De Jong D. The microarray way to tailored cancer treatment. Nat. Med. 8(1), 13-4 (2002).
109. Pfreundschuh M. Exploitation of the B-cell repertoire for the identification of human tumor antigens. Cancer Chemother. Pharmacol. 46 (Suppl), S3-7 (2000)